First Trust Advisors
NRIX icon

First Trust Advisors’s Nurix Therapeutics NRIX Stock Holding History

First Trust Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-135,903
Closed -$2.56M – 2595
2024
Q4 		$2.56M Buy
+135,903
New +$3.12M ﹤0.01% 1701

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors's NRIX Position: Q1 2025 in Review

First Trust Advisors sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 135,903 shares — an estimated $2.56M sold.

First Trust Advisors first reported a position in NRIX in Q4 2024 and held it in 1 quarter. The position peaked at $2.56M in Q4 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • First Trust Advisors reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • First Trust Advisors sold 135,903 Nurix Therapeutics shares in Q1 2025, an estimated $2.56M.
  • First Trust Advisors first reported a position in Nurix Therapeutics in Q4 2024 and held it in 1 quarter.
  • First Trust Advisors's Nurix Therapeutics position peaked at $2.56M in Q4 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on First Trust Advisors's 13F filing for Q1 2025, filed 14 May 2025.